Patients Can't Rescue Sarepta's Eteplirsen
This article was originally published in The Pink Sheet Daily
Executive Summary
Hours of testimony was clearly compelling, but advisory committee agreed with FDA concerns about the Duchenne muscular dystrophy drug's efficacy.